A 96-person randomized controlled trial found that Wuling capsules combined with nucleos(t)ide analogues produced higher HBV DNA seroconversion rates (67% vs 49%) and better liver function normalization than antivirals alone over 180 days, with no reported adverse effects. The study is methodologically sound but limited by small sample size and lack of mechanistic explanation for the herbal supplement's contribution.
Researchers in China conducted a multicenter randomized controlled trial to evaluate whether adding Wuling capsules (a traditional Chinese herbal preparation) to standard antiviral therapy improved outcomes in patients with chronic hepatitis B and low-level viremia. The trial enrolled 100 patients between December 2021 and March 2024, with 96 completing the full analysis: 47 received antivirals plus Wuling capsules, and 49 received antivirals alone.
After 180 days of treatment, the combination group showed measurably higher HBV DNA seroconversion rates: 67.39% achieved seroconversion compared to 48.98% in the control group. This difference reached statistical significance (p<0.05). The combination group also showed lower levels of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antibody (anti-HBc) compared to controls.
More practically for patient outcomes, the combination treatment group achieved higher normalization rates for liver enzymes. Specifically, alanine aminotransferase (ALT) normalized in 85.71% of the combination group versus 66.67% of controls; aspartate aminotransferase (AST) in 83.33% versus 60.00%; and gamma-glutamyl transferase in 100% versus 66.67%. Absolute values for these enzymes were also lower in the combination group. Bilirubin levels showed the same pattern: the combination group had levels of 12.69 micromol/L compared to 15.36 in controls.
Beyond laboratory markers, patients receiving Wuling capsules plus antivirals reported greater symptom improvement across pain, gastrointestinal complaints, and appetite. The study reported no adverse reactions attributed to Wuling capsules during the trial period.
This trial provides the type of evidence needed to evaluate adjunctive treatments in hepatitis B: a randomized design with control group comparison and objective outcome measures. However, several practical limitations apply.
First, this is a single trial from one healthcare system with a relatively small sample size. Before considering Wuling capsules as an adjunct to antiviral therapy, the findings would ideally be replicated in independent trials of larger populations and published in English-language journals for broader peer review scrutiny.
Second, the study doesn't explain why the herbal supplement improved outcomes. Without mechanistic data or active ingredient identification, it's unclear whether the benefit reflects the specific formulation, general immune support, improved treatment adherence due to symptom relief, or other factors. This limits ability to predict which patients would benefit most or whether similar formulations might work equally well.
Third, if you have chronic hepatitis B managed with antivirals, any consideration of additional supplementation should involve your hepatologist or infectious disease specialist. The apparent safety profile in this trial is reassuring but doesn't preclude interactions with individual antiviral regimens or other medications you may take.
| Characteristic | Details |
|---|---|
| Study type | Randomized controlled trial |
| Sample size | 100 enrolled; 96 completed (47 combination, 49 control) |
| Duration | 180 days treatment; recruitment Dec 2021 to Mar 2024 |
| Primary outcomes | HBV DNA seroconversion rate, hepatitis B serological markers, liver enzyme normalization |
| Secondary outcomes | Clinical symptom improvement (pain, belching, anorexia), bilirubin levels |
| Intervention | Nucleos(t)ide analogues + Wuling capsules (combination group) vs. nucleos(t)ide analogues alone (control) |
| Key findings | 67.39% vs 48.98% seroconversion; 85.71% vs 66.67% ALT normalization; 83.33% vs 60.00% AST normalization; 100% vs 66.67% gamma-glutamyl transferase normalization |
| Adverse events | None reported related to Wuling capsules |
| Journal | Zhonghua gan zang bing za zhi (Chinese Journal of Hepatology) |
| Limitations | Single-center recruitment despite "multicenter" designation; small sample; no mechanistic investigation; limited to 180-day follow-up |
Study: PubMed ID 42373438
Published in: Zhonghua gan zang bing za zhi = Chinese Journal of Hepatology
Note: This trial was conducted in China and published in a Chinese-language journal. The findings represent evidence from a single RCT and should be considered in context of the broader evidence base for hepatitis B management, which centers on nucleos(t)ide analogues and interferon-based therapies as standard of care.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.